白细胞介素-13 rs20541 单核苷酸多态性与哮喘患儿治疗效果的关系。
Relationship between interleukin-13 rs20541 single nucleotide polymorphisms and therapeutic efficacy in children with asthma.
机构信息
Shanghai Pudong Hospital, Shanghai, China.
Jinan Maternity and Child Care Hospital, Shandong, China.
出版信息
J Int Med Res. 2020 Jun;48(6):300060520929179. doi: 10.1177/0300060520929179.
OBJECTIVE
To investigate the relationship between therapeutic efficacy in children with asthma and interleukin-13 (IL-13) rs20541 polymorphisms.
METHODS
Fifty children with moderate-to-severe asthma were assigned to the GG, GA, and AA groups according to the IL-13 gene locus rs20541 polymorphism. The patients received budesonide inhalation suspension 1 mg twice daily combined with fluticasone propionate 80 µg/inhalation. The improvement of clinical symptoms (gasping, coughing, and wheezing), improvement of lung function, and adverse reactions were observed.
RESULTS
Lung function did not significantly differ among three groups before treatment. After treatment, the time to symptom relief was significantly shorter in the GG group than that in the other two groups. The forced expiratory volume in one second and percent predicted peak expiratory flow were also significantly better in the GG group than in the other two groups.
CONCLUSION
Budesonide inhalation suspension combined with fluticasone propionate is an effective treatment regimen for moderate-to-severe asthma. Polymorphism of the IL-13 rs20541 locus may be correlated with therapeutic efficacy. Patients carrying the GG allele were more responsive than their counterparts with the GA or AA allele.
目的
探讨白细胞介素-13（IL-13）rs20541 多态性与儿童哮喘疗效的关系。
方法
根据白细胞介素-13 基因座 rs20541 多态性，将 50 例中重度哮喘患儿分为 GG、GA 和 AA 组。患儿均给予布地奈德吸入混悬液 1mg，每日 2 次，联合丙酸氟替卡松 80μg/吸。观察临床症状（喘息、咳嗽、哮鸣音）改善情况、肺功能改善情况及不良反应。
结果
治疗前三组患儿肺功能比较，差异无统计学意义。治疗后 GG 组症状缓解时间明显短于其他两组，一秒用力呼气容积及预计值最高呼气流量也明显优于其他两组。
结论
布地奈德吸入混悬液联合丙酸氟替卡松是治疗中重度哮喘的有效方案。白细胞介素-13 rs20541 位点的多态性可能与疗效相关。携带 GG 等位基因的患者比携带 GA 或 AA 等位基因的患者反应更好。
Zotero 插件